Clear hydrogel corneal inlay with concurrent LASIK for presbyopia: multicenter commercial registry in Asian eyes

Session Details

Session Title: Intracorneal Inlays for Presbyopia

Session Date/Time: Tuesday 08/09/2015 | 16:00-18:00

Paper Time: 17:18

Venue: Main Auditorium

First Author: : H.Tchah SOUTH KOREA

Co Author(s): :    C. Joo   T. Kim   J. Kim   E. Cho           

Abstract Details

Purpose:

To report multicenter postoperative clinical results in presbyopes implanted with novel transparent corneal inlay (Raindrop Near Vision Inlay, ReVision Optics, Lake Forest, CA).

Setting:

Asan Medical Center, Seoul, Republic of Korea. Catholic Medical Center, Seoul, Republic of Korea. Yonsei Medical Center, Seoul, Republic of Korea.

Methods:

One hundred and sixty (n=160) patients were implanted with Raindrop Near Vision Inlay in various LASIK clinics in Japan and South Korea. Concurrent LASIK was used to treat ametropia and targeted to +0.25 D in the inlay eye (non-dominant) and plano in the fellow eye. Raindrop Inlay was delivered under a femtosecond flap and centered over the light constricted pupil above the stromal bed. Near and distance visual acuities were collected at preop, 1W, 1M, and 3M.

Results:

Patient age (mean ± SD) 51.7 ± 4.3 years old with 69% female and 31% male. Average preop CCT 536 ± 51 microns with flap depth of 153 ± 14 microns. Monocular (inlay eye) near visual acuities improved from (decimal) DCNVA: 0.31 at preop to UNVA: 0.73 at 3M. Binocular UVAs at 3M were 1.29 for distance and 0.78 for near. 4 cases (2.5%) of were noted with mild corneal haze. All resolved with a second round of steroids. 2 cases (1.2%) were explanted due to binocular imbalance and poor distance vision.

Conclusions:

Raindrop Inlay yielded good stable postop results with low complication rates. Postop refractions were targeted to be more myopic due to the increased near demands of the local population. Raindrop Inlay appears to be a safe and effective treatment for presbyopia in the Asian population.

Financial Interest:

One of the authors receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented.